Kai Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Kai Wang has a total of 221 co-authors. Here are the top co-authors by number of shared publications:
- Hongwei Liu
State Key Laboratory of Microbial Diversity and Innovative Utilization, Institute of Microbiology, Chinese Academy of Sciences, Beijing 100101, China; Medical School, University of Chinese Academy of Sciences, Beijing 101408, China
18 shared publications Li Bao
State Key Laboratory of Mycology, Institute of Microbiology, Chinese Academy of Sciences, No. 1 Beichenxi Road, Chaoyang District, Beijing 100101, P. R. China; Savaid Medical School, University of Chinese Academy of Sciences, Beijing 100049, P. R. China
18 shared publicationsKe Ma
State Key Laboratory of Mycology, Institute of Microbiology, Chinese Academy of Sciences, No. 1 Beichenxi Road, Chaoyang District, Beijing 100101, P. R. China; Savaid Medical School, University of Chinese Academy of Sciences, Beijing 100049, P. R. China
13 shared publications- Changtao Jiang
Department of Immunology, School of Basic Medical Sciences, Peking University, Beijing, China
10 shared publications - Jie Qiao
State Key Laboratory of Female Fertility Promotion, Center for Reproductive Medicine, Department of Obstetrics and Gynecology, Peking University Third Hospital, Beijing, China
5 shared publications Jinjin Zhang
State Key Laboratory of Mycology, Institute of Microbiology, Chinese Academy of Sciences, Beijing, PR China; Savaid Medical School, University of Chinese Academy of Sciences, Beijing, PR China
5 shared publications
Latest Publications
- 5 November 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 394 (6824)
Targeting hormone conversion through dietary fiber improves polyendocrine metabolic ovarian syndrome
Excessive androgens serve as a primary driver for many phenotypic features of polyendocrine metabolic ovarian syndrome (PMOS). Although dietary fiber has been shown to alleviate PMOS, its effects on androgen concentrations and the underlying mechanisms remain unclear. In a clinical trial, we demonstrated that a dietary fiber combination consisting of inulin, resistant starch, and β-glucan reduces androgen concentrations in patients’ plasma. Mechanistically, dietary fiber increased the abundance of Bacteroides xylanisolven s, which converts androstenedione into a nonandrogenic secondary hormone metabolite we named coproandrosterone, which is further metabolized by gut microbiota into dihydro-coproandrosterone. This metabolic pathway was validated in a mouse model. These findings highlight the potential of dietary fiber to alleviate PMOS by modulating androgen homeostasis through gut microbiota, offering insights for prebiotic and probiotic therapies.
- 5 November 2026
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 394 (6824)
Targeting hormone conversion through dietary fiber improves polyendocrine metabolic ovarian syndrome
Excessive androgens serve as a primary driver for many phenotypic features of polyendocrine metabolic ovarian syndrome (PMOS). Although dietary fiber has been shown to alleviate PMOS, its effects on androgen concentrations and the underlying mechanisms remain unclear. In a clinical trial, we demonstrated that a dietary fiber combination consisting of inulin, resistant starch, and β-glucan reduces androgen concentrations in patients’ plasma. Mechanistically, dietary fiber increased the abundance of Bacteroides xylanisolven s, which converts androstenedione into a nonandrogenic secondary hormone metabolite we named coproandrosterone, which is further metabolized by gut microbiota into dihydro-coproandrosterone. This metabolic pathway was validated in a mouse model. These findings highlight the potential of dietary fiber to alleviate PMOS by modulating androgen homeostasis through gut microbiota, offering insights for prebiotic and probiotic therapies.
- Top Cited Papers
- 7 April 2026
- Published by Springer Nature in Nature Reviews Gastroenterology & Hepatology
The microbiome regulates host metabolic health and diseases through microbial enzymes
The microbiome is widely involved in host metabolism, with many omics studies suggesting that it is important for metabolic health. Although studies in this area have made great strides in furthering our understanding of the role of the microbiome in health and disease, key challenges still hinder the safe clinical application of gut microbiota-targeted therapies. These limitations include a lack of confirmation of causality between the gut microbiota and host health, insights into the molecular mechanisms by which the gut microbiota functions to affect host health, and the development of therapeutic strategies that accurately regulate the function of the gut microbiota towards specific microbial enzyme targets without affecting its overall composition and viability. Microbial enzymes with various functions and activities have attracted the attention of many researchers in the past few years, especially microbiota-host isozymes, which are enzymes in the microbiome and the host that share a similar function. Such isozymes, as well as microbial-specific enzymes involved in basic biological processes of the gut microbiota, metabolism of nutrients, and synthesis of active metabolites and interactions in microbial-host communities, are the key mediators of gut microbiota-host crosstalk and have received much attention. In this Review, we provide a holistic understanding of the multifaceted role of gut microbial enzymes, including providing guidance for their discovery, while highlighting the great potential of gut microbial enzyme-oriented therapies for precision medicine.
- 7 April 2026
- Published by Springer Nature in Nature Reviews Gastroenterology & Hepatology
Top Cited PapersThe microbiome regulates host metabolic health and diseases through microbial enzymes
The microbiome is widely involved in host metabolism, with many omics studies suggesting that it is important for metabolic health. Although studies in this area have made great strides in furthering our understanding of the role of the microbiome in health and disease, key challenges still hinder the safe clinical application of gut microbiota-targeted therapies. These limitations include a lack of confirmation of causality between the gut microbiota and host health, insights into the molecular mechanisms by which the gut microbiota functions to affect host health, and the development of therapeutic strategies that accurately regulate the function of the gut microbiota towards specific microbial enzyme targets without affecting its overall composition and viability. Microbial enzymes with various functions and activities have attracted the attention of many researchers in the past few years, especially microbiota-host isozymes, which are enzymes in the microbiome and the host that share a similar function. Such isozymes, as well as microbial-specific enzymes involved in basic biological processes of the gut microbiota, metabolism of nutrients, and synthesis of active metabolites and interactions in microbial-host communities, are the key mediators of gut microbiota-host crosstalk and have received much attention. In this Review, we provide a holistic understanding of the multifaceted role of gut microbial enzymes, including providing guidance for their discovery, while highlighting the great potential of gut microbial enzyme-oriented therapies for precision medicine.
- 27 February 2026
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 138 (5) , e326979
Understanding the Role of Gut Microbial Enzyme in CMD
Cardiometabolic diseases (CMDs) refer to a broad spectrum of interconnected disorders, including heart attack, obesity, diabetes, atherosclerosis, and metabolic dysfunction–associated steatohepatitis, which represent the leading cause of mortality worldwide. In recent years, research on the role of gut microbiota in the pathogenesis of CMD has gradually shifted from correlation-based observations to mechanistic explorations. Within this context, microbial enzymes have gained increasing attention as key regulatory factors. These enzymes not only participate in the metabolic regulation of microorganisms themselves but also directly mediate host-microbe interactions, influencing the onset and progression of CMD. Specifically, microbial enzymes play a central role in CMD by modulating the homeostasis of key host metabolites such as cholesterol, generating bioactive molecules with metabolic and immunoregulatory functions, and participating in drug responses and the metabolic transformation of other xenobiotics. These enzymes provide novel and well-defined molecular targets for developing precision intervention strategies targeting the gut microbiota—such as enzyme replacement therapy, the design of enzyme agonists or inhibitors, and in vivo gene editing—thereby holding promise for advancing CMD prevention and treatment strategies toward greater specificity and controllability. This review systematically summarizes key microbial enzymes involved in the metabolism of endobiotics, including amino acids, peptides, and purines, and xenobiotics such as drugs, elucidating their specific mechanisms and functions in the development of CMD, strategies for mining these microbial enzymes, and the challenges and future of microbial enzyme-based interventions.
- 27 February 2026
- Published by Wolters Kluwer Health in Circulation Research
- Vol. 138 (5) , e326979
Understanding the Role of Gut Microbial Enzyme in CMD
Cardiometabolic diseases (CMDs) refer to a broad spectrum of interconnected disorders, including heart attack, obesity, diabetes, atherosclerosis, and metabolic dysfunction–associated steatohepatitis, which represent the leading cause of mortality worldwide. In recent years, research on the role of gut microbiota in the pathogenesis of CMD has gradually shifted from correlation-based observations to mechanistic explorations. Within this context, microbial enzymes have gained increasing attention as key regulatory factors. These enzymes not only participate in the metabolic regulation of microorganisms themselves but also directly mediate host-microbe interactions, influencing the onset and progression of CMD. Specifically, microbial enzymes play a central role in CMD by modulating the homeostasis of key host metabolites such as cholesterol, generating bioactive molecules with metabolic and immunoregulatory functions, and participating in drug responses and the metabolic transformation of other xenobiotics. These enzymes provide novel and well-defined molecular targets for developing precision intervention strategies targeting the gut microbiota—such as enzyme replacement therapy, the design of enzyme agonists or inhibitors, and in vivo gene editing—thereby holding promise for advancing CMD prevention and treatment strategies toward greater specificity and controllability. This review systematically summarizes key microbial enzymes involved in the metabolism of endobiotics, including amino acids, peptides, and purines, and xenobiotics such as drugs, elucidating their specific mechanisms and functions in the development of CMD, strategies for mining these microbial enzymes, and the challenges and future of microbial enzyme-based interventions.
- Open Access
- 30 January 2026
- Published by Springer Nature in Research Square
Intestinal probiotic fungi improve PCOS by sensing metformin signaling and inhibiting gut derived ceramide levels
Polycystic ovary syndrome (PCOS) is the leading cause of anovulatory infertility. Although metformin improves metabolic dysfunction in PCOS, its therapeutic potential in non-insulin-resistant patients and the role in mediating gut fungi remain unexplored. We followed up with PCOS patients who received metformin for clinical treatment, and the results showed that metformin significantly improved reproductive function in non-insulin resistant PCOS patients. We identified Alternaria alternata (A. alternata) as a metformin-enriched gut fungus that alleviates PCOS in mice by suppressing the intestinal SMPD3, thereby reducing ceramide levels and endoplasmic reticulum stress in granulosa cells to improve ovarian function. Notably, we validated γ-tocotrienol as the key A. alternata metabolite mediating these therapeutic effects, and conformed its upregulation post-metformin treatment in PCOS patients, correlating with improved clinical characteristics. Our findings reveal that metformin improves PCOS by modulating gut fungi and inhibiting ceramide synthesis, offering a promising therapeutic strategy for non-insulin-resistant PCOS.
- 30 January 2026
- Published by Springer Nature in Research Square
Open AccessIntestinal probiotic fungi improve PCOS by sensing metformin signaling and inhibiting gut derived ceramide levels
Polycystic ovary syndrome (PCOS) is the leading cause of anovulatory infertility. Although metformin improves metabolic dysfunction in PCOS, its therapeutic potential in non-insulin-resistant patients and the role in mediating gut fungi remain unexplored. We followed up with PCOS patients who received metformin for clinical treatment, and the results showed that metformin significantly improved reproductive function in non-insulin resistant PCOS patients. We identified Alternaria alternata (A. alternata) as a metformin-enriched gut fungus that alleviates PCOS in mice by suppressing the intestinal SMPD3, thereby reducing ceramide levels and endoplasmic reticulum stress in granulosa cells to improve ovarian function. Notably, we validated γ-tocotrienol as the key A. alternata metabolite mediating these therapeutic effects, and conformed its upregulation post-metformin treatment in PCOS patients, correlating with improved clinical characteristics. Our findings reveal that metformin improves PCOS by modulating gut fungi and inhibiting ceramide synthesis, offering a promising therapeutic strategy for non-insulin-resistant PCOS.
- Top Cited Papers
- 1 May 2025
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 388 (6746) , eadp5540
A symbiotic filamentous gut fungus ameliorates MASH via a secondary metabolite–CerS6–ceramide axis
The gut microbiota is known to be associated with a variety of human metabolic diseases, including metabolic dysfunction–associated steatohepatitis (MASH). Fungi are increasingly recognized as important members of this community; however, the role of fungal symbionts in metabolic diseases is unknown. We have systematically isolated and characterized gut fungi, identifying Fusarium foetens as an intestinal symbiotic filamentous fungus in mice. F. foetens reverses MASH progression in mouse models through an intestinal ceramide synthetase 6 (CerS6)–ceramide axis. Moreover, we identified FF-C1, a secondary metabolite from F. foetens , as a CerS6 inhibitor that has an endogenous protective effect on MASH progression.
- 1 May 2025
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 388 (6746) , eadp5540
Top Cited PapersA symbiotic filamentous gut fungus ameliorates MASH via a secondary metabolite–CerS6–ceramide axis
The gut microbiota is known to be associated with a variety of human metabolic diseases, including metabolic dysfunction–associated steatohepatitis (MASH). Fungi are increasingly recognized as important members of this community; however, the role of fungal symbionts in metabolic diseases is unknown. We have systematically isolated and characterized gut fungi, identifying Fusarium foetens as an intestinal symbiotic filamentous fungus in mice. F. foetens reverses MASH progression in mouse models through an intestinal ceramide synthetase 6 (CerS6)–ceramide axis. Moreover, we identified FF-C1, a secondary metabolite from F. foetens , as a CerS6 inhibitor that has an endogenous protective effect on MASH progression.
- 26 November 2024
- Published by Wolters Kluwer Health in Circulation
- Vol. 150 (22) , 1791-1811
Extracellular RIPK3 Acts as a Damage-Associated Molecular Pattern to Exaggerate Cardiac Ischemia/Reperfusion Injury
BACKGROUND: Cardiac ischemia/reperfusion (I/R) injury has emerged as an important therapeutic target for ischemic heart disease. Currently, there is no effective therapy for reducing cardiac I/R injury. Damage-associated molecular patterns are endogenous molecules released after cellular damage to exaggerate tissue inflammation and injury. RIPK3 (receptor-interacting protein kinase 3), a well-established intracellular mediator of cell necroptosis and inflammation, serves as a circulating biomarker of multiple diseases. However, whether extracellular RIPK3 also exerts biological functions in cardiac I/R injury remains totally unknown. METHODS: Patients with acute myocardial infarction receiving percutaneous coronary intervention (PCI) were recruited independently in the discovery cohort (103 patients) and validation cohort (334 patients), and major adverse cardiovascular events were recorded. Plasma samples were collected before and after PCI (6 and 24 h) for RIPK3 concentration measurement. Cultured neonatal rat ventricular myocytes, macrophages and endothelial cells, and in vivo mouse models with myocardial injury induced by I/R (or hypoxia/reoxygenation) were used to investigate the role and mechanisms of extracellular RIPK3. Another cohort including patients with acute myocardial infarction receiving PCI and healthy volunteers was recruited to further explore the mechanisms of extracellular RIPK3. RESULTS: In the discovery cohort, elevated plasma RIPK3 levels after PCI are associated with poorer short- and long-term outcomes in patients with acute myocardial infarction, as confirmed in the validation cohort. In both cultured cells and in vivo mouse models, recombinant RIPK3 protein exaggerated myocardial I/R (or hypoxia/reoxygenation) injury, which was alleviated by the RIPK3 antibody. Mechanistically, RIPK3 acted as a damage-associated molecular pattern and bound with RAGE (receptor of advanced glycation end-products), subsequently activating CaMKII (Ca 2+ /calmodulin-dependent kinase II) to elicit the detrimental effects. The positive correlation between plasma RIPK3 concentrations and CaMKII phosphorylation in human peripheral blood mononuclear cells was confirmed. CONCLUSIONS: We identified the positive relationship between plasma RIPK3 concentrations and the risk of major adverse cardiovascular events in patients with acute myocardial infarction receiving PCI. As a damage-associated molecular pattern, extracellular RIPK3 plays a causal role in multiple pathological conditions during cardiac I/R injury through RAGE/CaMKII signaling. These findings expand our understanding of the physiological and pathological roles of RIPK3, and also provide a promising therapeutic target for myocardial I/R injury and the associated complications.
- 26 November 2024
- Published by Wolters Kluwer Health in Circulation
- Vol. 150 (22) , 1791-1811
Extracellular RIPK3 Acts as a Damage-Associated Molecular Pattern to Exaggerate Cardiac Ischemia/Reperfusion Injury
BACKGROUND: Cardiac ischemia/reperfusion (I/R) injury has emerged as an important therapeutic target for ischemic heart disease. Currently, there is no effective therapy for reducing cardiac I/R injury. Damage-associated molecular patterns are endogenous molecules released after cellular damage to exaggerate tissue inflammation and injury. RIPK3 (receptor-interacting protein kinase 3), a well-established intracellular mediator of cell necroptosis and inflammation, serves as a circulating biomarker of multiple diseases. However, whether extracellular RIPK3 also exerts biological functions in cardiac I/R injury remains totally unknown. METHODS: Patients with acute myocardial infarction receiving percutaneous coronary intervention (PCI) were recruited independently in the discovery cohort (103 patients) and validation cohort (334 patients), and major adverse cardiovascular events were recorded. Plasma samples were collected before and after PCI (6 and 24 h) for RIPK3 concentration measurement. Cultured neonatal rat ventricular myocytes, macrophages and endothelial cells, and in vivo mouse models with myocardial injury induced by I/R (or hypoxia/reoxygenation) were used to investigate the role and mechanisms of extracellular RIPK3. Another cohort including patients with acute myocardial infarction receiving PCI and healthy volunteers was recruited to further explore the mechanisms of extracellular RIPK3. RESULTS: In the discovery cohort, elevated plasma RIPK3 levels after PCI are associated with poorer short- and long-term outcomes in patients with acute myocardial infarction, as confirmed in the validation cohort. In both cultured cells and in vivo mouse models, recombinant RIPK3 protein exaggerated myocardial I/R (or hypoxia/reoxygenation) injury, which was alleviated by the RIPK3 antibody. Mechanistically, RIPK3 acted as a damage-associated molecular pattern and bound with RAGE (receptor of advanced glycation end-products), subsequently activating CaMKII (Ca 2+ /calmodulin-dependent kinase II) to elicit the detrimental effects. The positive correlation between plasma RIPK3 concentrations and CaMKII phosphorylation in human peripheral blood mononuclear cells was confirmed. CONCLUSIONS: We identified the positive relationship between plasma RIPK3 concentrations and the risk of major adverse cardiovascular events in patients with acute myocardial infarction receiving PCI. As a damage-associated molecular pattern, extracellular RIPK3 plays a causal role in multiple pathological conditions during cardiac I/R injury through RAGE/CaMKII signaling. These findings expand our understanding of the physiological and pathological roles of RIPK3, and also provide a promising therapeutic target for myocardial I/R injury and the associated complications.
- Top Cited Papers
- 20 May 2024
- Published by Springer Nature in Nature Metabolism
- Vol. 6 (5) , 947-962
The microbial metabolite agmatine acts as an FXR agonist to promote polycystic ovary syndrome in female mice
Polycystic ovary syndrome (PCOS), an endocrine disorder afflicting 6–20% of women of reproductive age globally, has been linked to alterations in the gut microbiome. We previously showed that in PCOS, elevation of Bacteroides vulgatus in the gut microbiome was associated with altered bile acid metabolism. Here we show that B. vulgatus also induces a PCOS-like phenotype in female mice via an alternate mechanism independent of bile acids. We find that B. vulgatus contributes to PCOS-like symptoms through its metabolite agmatine, which is derived from arginine by arginine decarboxylase. Mechanistically, agmatine activates the farnesoid X receptor (FXR) pathway to subsequently inhibit glucagon-like peptide-1 (GLP-1) secretion by L cells, which leads to insulin resistance and ovarian dysfunction. Critically, the GLP-1 receptor agonist liraglutide and the arginine decarboxylase inhibitor difluoromethylarginine ameliorate ovarian dysfunction in a PCOS-like mouse model. These findings reveal that agmatine–FXR–GLP-1 signalling contributes to ovarian dysfunction, presenting a potential therapeutic target for PCOS management.
- 20 May 2024
- Published by Springer Nature in Nature Metabolism
- Vol. 6 (5) , 947-962
Top Cited PapersThe microbial metabolite agmatine acts as an FXR agonist to promote polycystic ovary syndrome in female mice
Polycystic ovary syndrome (PCOS), an endocrine disorder afflicting 6–20% of women of reproductive age globally, has been linked to alterations in the gut microbiome. We previously showed that in PCOS, elevation of Bacteroides vulgatus in the gut microbiome was associated with altered bile acid metabolism. Here we show that B. vulgatus also induces a PCOS-like phenotype in female mice via an alternate mechanism independent of bile acids. We find that B. vulgatus contributes to PCOS-like symptoms through its metabolite agmatine, which is derived from arginine by arginine decarboxylase. Mechanistically, agmatine activates the farnesoid X receptor (FXR) pathway to subsequently inhibit glucagon-like peptide-1 (GLP-1) secretion by L cells, which leads to insulin resistance and ovarian dysfunction. Critically, the GLP-1 receptor agonist liraglutide and the arginine decarboxylase inhibitor difluoromethylarginine ameliorate ovarian dysfunction in a PCOS-like mouse model. These findings reveal that agmatine–FXR–GLP-1 signalling contributes to ovarian dysfunction, presenting a potential therapeutic target for PCOS management.
- Top Cited Papers
- 17 January 2024
- Published by Springer Nature in Nature Microbiology
- Vol. 9 (2) , 434-450
Gut commensal Christensenella minuta modulates host metabolism via acylated secondary bile acids
A strong correlation between gut microbes and host health has been observed in numerous gut metagenomic cohort studies. However, the underlying mechanisms governing host–microbe interactions in the gut remain largely unknown. Here we report that the gut commensal Christensenella minuta modulates host metabolism by generating a previously undescribed class of secondary bile acids with 3-O-acylation substitution that inhibit the intestinal farnesoid X receptor. Administration of C. minuta alleviated features of metabolic disease in high fat diet-induced obese mice associated with a significant increase in these acylated bile acids, which we refer to as 3-O-acyl-cholic acids. Specific knockout of intestinal farnesoid X receptor in mice counteracted the beneficial effects observed in their wild-type counterparts. Finally, we showed that 3-O-acyl-CAs were prevalent in healthy humans but significantly depleted in patients with type 2 diabetes. Our findings indicate a role for C. minuta and acylated bile acids in metabolic diseases.
- 17 January 2024
- Published by Springer Nature in Nature Microbiology
- Vol. 9 (2) , 434-450
Top Cited PapersGut commensal Christensenella minuta modulates host metabolism via acylated secondary bile acids
A strong correlation between gut microbes and host health has been observed in numerous gut metagenomic cohort studies. However, the underlying mechanisms governing host–microbe interactions in the gut remain largely unknown. Here we report that the gut commensal Christensenella minuta modulates host metabolism by generating a previously undescribed class of secondary bile acids with 3-O-acylation substitution that inhibit the intestinal farnesoid X receptor. Administration of C. minuta alleviated features of metabolic disease in high fat diet-induced obese mice associated with a significant increase in these acylated bile acids, which we refer to as 3-O-acyl-cholic acids. Specific knockout of intestinal farnesoid X receptor in mice counteracted the beneficial effects observed in their wild-type counterparts. Finally, we showed that 3-O-acyl-CAs were prevalent in healthy humans but significantly depleted in patients with type 2 diabetes. Our findings indicate a role for C. minuta and acylated bile acids in metabolic diseases.
- Top Cited Papers
- 4 August 2023
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 381 (6657) , 501-+
Microbial-host-isozyme analyses reveal microbial DPP4 as a potential antidiabetic target
A mechanistic understanding of how microbial proteins affect the host could yield deeper insights into gut microbiota–host cross-talk. We developed an enzyme activity–screening platform to investigate how gut microbiota–derived enzymes might influence host physiology. We discovered that dipeptidyl peptidase 4 (DPP4) is expressed by specific bacterial taxa of the microbiota. Microbial DPP4 was able to decrease the active glucagon like peptide-1 (GLP-1) and disrupt glucose metabolism in mice with a leaky gut. Furthermore, the current drugs targeting human DPP4, including sitagliptin, had little effect on microbial DPP4. Using high-throughput screening, we identified daurisoline-d4 (Dau-d4) as a selective microbial DPP4 inhibitor that improves glucose tolerance in diabetic mice.
- 4 August 2023
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 381 (6657) , 501-+
Top Cited PapersMicrobial-host-isozyme analyses reveal microbial DPP4 as a potential antidiabetic target
A mechanistic understanding of how microbial proteins affect the host could yield deeper insights into gut microbiota–host cross-talk. We developed an enzyme activity–screening platform to investigate how gut microbiota–derived enzymes might influence host physiology. We discovered that dipeptidyl peptidase 4 (DPP4) is expressed by specific bacterial taxa of the microbiota. Microbial DPP4 was able to decrease the active glucagon like peptide-1 (GLP-1) and disrupt glucose metabolism in mice with a leaky gut. Furthermore, the current drugs targeting human DPP4, including sitagliptin, had little effect on microbial DPP4. Using high-throughput screening, we identified daurisoline-d4 (Dau-d4) as a selective microbial DPP4 inhibitor that improves glucose tolerance in diabetic mice.